EMA grants orphan drug designation to Cornerstone Pharmaceuticals' CPI-613 (devimistat)

Cornerstone Pharmaceuticals has announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to CPI-613 (devimistat) to treat advanced unresectable biliary tract cancer.

Related Keywords

United Kingdom ,Vaibhav Sahai ,Sanjeev Luther ,Drug Administration ,Cornerstone Pharmaceuticals ,